Black Box Warning for Two Anti-Smoking Drugs

Published by Alexis Pellek on July 2, 2009 under Packaging & Labeling, Products, Regulation

Alexis Brekke Pellek PharmTech editorThe US Food and Drug Administration announced yesterday it is requiring a black box warning for two drugs used to aid smoking cessation, Chantix (varenicline, Pfizer, New York) and Zyban (bupropion, GlaxoSmithKline, London). Read more »

Add a Comment // 0 Comments »

Fighting Drug Abuse with Drug Delivery

Published by Erik Greb on June 29, 2009 under Drug Delivery, Formulation, Manufacturing, North America News, Regulation, Trends

Add a Comment // 0 Comments »

The Seven-Year Itch in Biologics Exclusivity

Published by Patricia Van Arnum on June 26, 2009 under Biotech, Regulation

Add a Comment // 1 Comment »

Counterfeit Pharmaceuticals on the Internet

Published by Alexis Pellek on June 25, 2009 under Products, Trends

Add a Comment // 0 Comments »

AAPS National Biotech Conference: Refocus on Science and QbD

Published by Maribel Rios on June 23, 2009 under Biotech, Industry conferences, R&D

Add a Comment // 0 Comments »

Would Comparative Effectiveness Reduce Patients’ Options?

Published by Erik Greb on June 22, 2009 under North America News, Regulation, Trends

Add a Comment // 2 Comments »

Big Pharma’s “BRIC and Mortar” Strategy

Published by Patricia Van Arnum on June 19, 2009 under Asia News, Latin & South America News, Trends

Add a Comment // 0 Comments »

Predicting Gaps in the Supply Chain

Published by Angie Drakulich on June 17, 2009 under Industry conferences, Trends

Add a Comment // 1 Comment »

FDA Issues Warning Over Matrixx Intiatives’ Zicam

Published by Maribel Rios on June 16, 2009 under Regulation

Add a Comment // 4 Comments »

What is Fair for Drug Exclusivity?

Published by Patricia Van Arnum on June 12, 2009 under Biotech, Regulation

Add a Comment // 2 Comments »

Next Page »